ADDEX THERAPEUTICS L

ADXN
Delayed Quote. Delayed  - 05/12 11:32:00 am
1.45CHF -2.03%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 3,881,32
EBITDA1 -11,9-15,8
Operating profit (EBIT)1 -12,2-15,5
Operating Margin -316%-1 176%
Pre-Tax Profit (EBT)1 -12,9-15,1
Net income1 -12,9-15,1
Net margin -332%-1 142%
EPS2 -0,48-0,43
Dividend per Share2 --
Last update 03/11/202101/05/2021
1 CHF in Million
2 CHF
Estimates
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 18,811,0
Leverage (Debt / EBITDA) 1,58x0,70x
Free Cash Flow1 -12,2-18,1
ROE (Net Profit / Equities) --
Shareholders' equity1 --
ROA (Net Profit / Asset) --
Assets1 --
Book Value Per Share2 0,540,23
Cash Flow per Share2 -0,46-0,62
Capex1 0,060,22
Capex / Sales 1,53%16,7%
Last update 03/11/202105/06/2021
1 CHF in Million
2 CHF
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 63 M CHF -
Entreprise Value (EV) 52,1 M CHF 86,0 M CHF
Valuation 2021e 2022e
P/E ratio (Price / EPS) -3,37x -2,03x
Capitalization / Revenue 47,9x 52,2x
EV / Revenue 39,6x 43,1x
EV / EBITDA -3,30x -2,13x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 6,30x -1,79x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -1 176% -1 875%
Operating Leverage (Delta EBIT / Delta Sales) -0,40x -5,57x
Net Margin (Net Profit / Revenue) -1 142% -2 126%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   16,7% 19,9%
Cash Flow / Sales -2 044% -2 040%
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -0,93x
Price Earning Ratio
EPS & Dividend